Kolistimetatnatrij Accord

Colistimethate sodium, the active ingredient in Kolistimetatnatrij Accord, is a polymyxin antibiotic presented as an intravenous formulation for use in severe Gram‑negative bacterial infections, including those caused by Pseudomonas aeruginosa. It is administered under medical supervision to patients with life‑threatening infections where other antibiotics may be ineffective.

GNH USA supplies Kolistimetatnatrij Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kolistimetatnatrij Accord is used to treat infections caused by susceptible Gram‑negative bacteria, acting on the bacterial cell membrane to eradicate the pathogen.

- Pseudomonas aeruginosa infections: eradicates the pathogen and helps resolve the infection. - Hospital‑acquired pneumonia: reduces bacterial load and improves respiratory function. - Ventilator‑associated pneumonia: targets resistant Gram‑negative organisms to aid recovery. - Bloodstream infections (septicemia): clears bacteremia and supports systemic infection control.

Colistimethate sodium may cause a range of adverse reactions, from mild to severe. Monitoring patients for these effects is essential during therapy.

Common Side Effects: - Nephrotoxicity: elevated serum creatinine and reduced renal function. - Neurotoxicity: paresthesia, dizziness, or headache. - Nausea and vomiting: gastrointestinal discomfort. - Rash or mild skin irritation. - Fever: transient temperature elevation.

Serious or Rare Side Effects: - Acute renal failure: rapid decline in kidney function requiring intervention. - Respiratory paralysis: especially when combined with neuromuscular blockers. - Anaphylaxis: severe allergic reaction with hypotension and airway compromise. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Ototoxicity: hearing loss or tinnitus.

When using Kolistimetatnatrij Accord, clinicians should consider several safety measures to minimize risk. - Renal monitoring: assess serum creatinine and urine output regularly. - Neurotoxicity vigilance: watch for signs of peripheral neuropathy or seizures. - Pre‑existing kidney disease: adjust therapy and monitor closely. - Neuromuscular disorders: avoid concurrent use with agents that may enhance blockade. - Concomitant nephrotoxic drugs: limit or monitor dosage when used together. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Colistimetatnatrij Accord can interact with other medicines, affecting safety and efficacy.

Major Interactions (Avoid): - Aminoglycosides: additive nephrotoxicity. - Loop diuretics: increased risk of renal impairment. - Vancomycin: heightened renal toxicity. - Neuromuscular blocking agents: enhanced respiratory muscle weakness.

Moderate Interactions (Monitor Closely): - NSAIDs: may worsen kidney function. - ACE inhibitors or ARBs: potential for reduced renal clearance. - Other nephrotoxic antibiotics: monitor renal parameters closely.